Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results ...

Dupixent was previously granted orphan drug designation by ... and painful lesions. The blisters and rash can form over much of the body and cause the skin to bleed and crust, resulting in patients ...

The study met its primary endpoint, but analysts compared the results unfavorably to the data on Dupixent. Adjusted for placebo, 19.1% of people on rocatinlimab had 75% improvement in eczema area ...

Dupixent was previously granted Orphan Drug Designation by ... in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024.

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating moderate-to-severe bullous pemphigoid (BP). The findings were presented at the 2025 ...

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest ...

Last year, Dupixent was among the 10 best-selling drugs ... One of them is a gene therapy for a rare form of congenital deafness that is already producing highly encouraging results.

Dupixent was previously granted Orphan Drug Designation by ... and painful lesions. The blisters and rash can form over much of the body and cause the skin to bleed and crust, resulting in patients ...